Literature DB >> 15254160

Adeno-associated virus site-specific integration and AAVS1 disruption.

Henry Hamilton1, Janette Gomos, Kenneth I Berns, Erik Falck-Pedersen.   

Abstract

Adeno-associated virus (AAV) is a single-stranded DNA virus with a unique biphasic lifestyle consisting of both a productive and a latent phase. Typically, the productive phase requires coinfection with a helper virus, for instance adenovirus, while the latent phase dominates in healthy cells. In the latent state, AAV is found integrated site specifically into the host genome at chromosome 19q13.4 qtr (AAVS1), the only animal virus known to integrate in a defined location. In this study we investigated the latent phase of serotype 2 AAV, focusing on three areas: AAV infection, rescue, and integration efficiency as a function of viral multiplicity of infection (MOI); efficiency of site-specific integration; and disruption of the AAVS1 locus. As expected, increasing the AAV MOI resulted in an increase in the percentage of cells infected, with 80% of cells infected at an MOI of 10. Additional MOI only marginally effected a further increase in percentage of infected cells. In contrast to infection, we found very low levels of integration at MOIs of less than 10. At an MOI of 10, at which 80% of cells are infected, less than 5% of clonal cell lines contained integrated AAV DNA. At an MOI of 100 or greater, however, 35 to 40% of clonal cell lines contained integrated AAV DNA. Integration and the ability to rescue viral genomes were highly correlated. Analysis of integrated AAV indicated that essentially all integrants were AAVS1 site specific. Although maximal integration efficiency approached 40% of clonal cell lines (essentially 50% of infected cells), over 80% of cell lines contained a genomic disruption at the AAVS1 integration locus on chromosome 19 ( approximately 100% of infected cells). Rep expression by itself and in the presence of a plasmid integration substrate was able to mediate this disruption of the AAVS1 site. We further characterized the disruption event and demonstrated that it resulted in amplification of the AAVS1 locus. The data are consistent with a revised model of AAV integration that includes preliminary expansion of a defined region in AAVS1.

Entities:  

Mesh:

Year:  2004        PMID: 15254160      PMCID: PMC446113          DOI: 10.1128/JVI.78.15.7874-7882.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.

Authors:  S Zolotukhin; B J Byrne; E Mason; I Zolotukhin; M Potter; K Chesnut; C Summerford; R J Samulski; N Muzyczka
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

2.  Adeno-associated virus site-specifically integrates into a muscle-specific DNA region.

Authors:  N Dutheil; F Shi; T Dupressoir; R M Linden
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

3.  Production and purification of recombinant adeno-associated virus.

Authors:  W W Hauswirth; A S Lewin; S Zolotukhin; N Muzyczka
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

4.  DNA sequence motifs which direct adeno-associated virus site-specific integration in a model system.

Authors:  P Meneses; K I Berns; E Winocour
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model.

Authors:  C Meyers; M Mane; N Kokorina; S Alam; P L Hermonat
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

6.  Introduction of single base substitutions at homologous chromosomal sequences by adeno-associated virus vectors.

Authors:  N Inoue; R Dong; R K Hirata; D W Russell
Journal:  Mol Ther       Date:  2001-04       Impact factor: 11.454

7.  Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors.

Authors:  J S Bartlett; R Wilcher; R J Samulski
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton.

Authors:  I Tan; C H Ng; L Lim; T Leung
Journal:  J Biol Chem       Date:  2001-04-03       Impact factor: 5.157

9.  Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation.

Authors:  S Sanlioglu; P K Benson; J Yang; E M Atkinson; T Reynolds; J F Engelhardt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat.

Authors:  S M Young; R J Samulski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

View more
  20 in total

1.  A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette.

Authors:  Hongjie Wang; André Lieber
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

2.  Adeno-associated virus type 2 p5 promoter: a rep-regulated DNA switch element functioning in transcription, replication, and site-specific integration.

Authors:  Mary Murphy; Janette Gomos-Klein; Marko Stankic; Erik Falck-Pedersen
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

Review 3.  Strategies to circumvent humoral immunity to adeno-associated viral vectors.

Authors:  Longping V Tse; Sven Moller-Tank; Aravind Asokan
Journal:  Expert Opin Biol Ther       Date:  2015-06       Impact factor: 4.388

4.  Adeno-associated virus site-specific integration is regulated by TRP-185.

Authors:  Noriaki Yamamoto; Masato Suzuki; Masa-Aki Kawano; Takamasa Inoue; Ryou-U Takahashi; Hiroko Tsukamoto; Teruya Enomoto; Yuki Yamaguchi; Tadashi Wada; Hiroshi Handa
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

5.  Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy.

Authors:  J Adriaansen; S W Tas; P L Klarenbeek; A C Bakker; F Apparailly; G S Firestein; C Jorgensen; M J B M Vervoordeldonk; P P Tak
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

6.  Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse.

Authors:  A Flierl; Y Chen; P E Coskun; R J Samulski; D C Wallace
Journal:  Gene Ther       Date:  2005-04       Impact factor: 5.250

7.  Site-specific integration of adeno-associated virus involves partial duplication of the target locus.

Authors:  Els Henckaerts; Nathalie Dutheil; Nadja Zeltner; Steven Kattman; Erik Kohlbrenner; Peter Ward; Nathalie Clément; Patricia Rebollo; Marion Kennedy; Gordon M Keller; R Michael Linden
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

8.  High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration.

Authors:  Tyler Janovitz; Isaac A Klein; Thiago Oliveira; Piali Mukherjee; Michel C Nussenzweig; Michel Sadelain; Erik Falck-Pedersen
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

9.  Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome.

Authors:  Daniela Hüser; Andreas Gogol-Döring; Timo Lutter; Stefan Weger; Kerstin Winter; Eva-Maria Hammer; Toni Cathomen; Knut Reinert; Regine Heilbronn
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

10.  Substitution of adeno-associated virus Rep protein binding and nicking sites with human chromosome 19 sequences.

Authors:  Victor J McAlister; Roland A Owens
Journal:  Virol J       Date:  2010-09-08       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.